Browse Studies — Arctuva

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to N…

NASH - Nonalcoholic SteatohepatitisMASH - Metabolic Dysfunction-Associated Steatohepatitis

Estimated

~$10 – $8,750

Akero Therapeutics, IncNCT06528314

Observational

Non-Invasive Quantification of Liver Health in NASH (N-QUAN): A Prospective Diagnostic Accuracy Study

To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those …

NASH - Nonalcoholic Steatohepatitis

Estimated

~$10 – $7,500

PerspectumNCT04054310

Observational

Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

Participants meeting study entry criteria are randomized with equal probability to one of two study groups: (1) Lifestyle modification or (2) Vertical Sleeve G…

NASH - Nonalcoholic Steatohepatitis

Estimated

~$10 – $6,250

University of MinnesotaNCT03587831

Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 1

This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how…

Obesity, MorbidNASH - Nonalcoholic SteatohepatitisChronic Inflammation

Estimated

~$10 – $750

Mayo ClinicNCT04232566